We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Marvel Biotechnology has reported a milestone in the development of its lead compound MB-204, entering into a current good manufacturing process (cGMP) manufacturing agreement with Zhejiang Ausun Pharmaceutical.